Beurs gesloten -
Andere beurzen
|
Nabeurs 22:36:51 | |||
48,93 USD | +1,30% | 48,69 | -0,49% |
18/04 | BRISTOL-MYERS SQUIBB COMPANY : Wells Fargo Securities is Neutraal gestemd over aandeel | ZM |
15/04 | BRISTOL-MYERS SQUIBB COMPANY : Wolfe Research herhaalt koopadvies | ZM |
Grafiek agenda Bristol-Myers Squibb Company
Komende gebeurtenissen op Bristol-Myers Squibb Company
Gebeurtenissen op naam
07-04-2024 19:45 | American College of Cardiology Scientific Meeting - Poster No 1075-09 |
07-04-2024 19:30 | American College of Cardiology Scientific Meeting - Poster No: 1075-07 |
07-04-2024 19:15 | American College of Cardiology Scientific Meeting - Abstract No: 1424-134 |
07-04-2024 18:00 | American College of Cardiology Scientific Meeting - Poster No: 1065-11 |
06-04-2024 20:45 | American College of Cardiology Scientific Meeting - Poster No: 1306-157 |
06-04-2024 19:45 | American College of Cardiology Scientific Meeting - Poster No: 1284-132 |
06-04-2024 17:45 | American College of Cardiology Scientific Meeting - Poster No: 1244-128 |
04-04-2024 | Onthechting van dividenddividend |
03-04-2024 | Schizophrenia International Research Society Congress |
15-03-2024 | Federal Register Oncologic Drugs Advisory Committee Meeting |
14-03-2024 13:30 | Barclays Global Healthcare Conference |
13-03-2024 15:00 | Leerink Partners Global Biopharma Conference |
04-03-2024 15:50 | TD Cowen Health Care Conference |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P47 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P47 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P35 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P09 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P09 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P35 |
29-02-2024 | Americas Committee for Treatment And Research in Multiple Sclerosis Forum - Presentation Number: P09 |
Dividenden van Bristol-Myers Squibb Company in het verleden
04-04-2024 | Kwartaaldividend 0.6 USD |
04-01-2024 | Kwartaaldividend 0.6 USD |
05-10-2023 | Kwartaaldividend 0.57 USD |
06-07-2023 | Kwartaaldividend 0.57 USD |
06-04-2023 | Kwartaaldividend 0.57 USD |
05-01-2023 | Kwartaaldividend 0.57 USD |
06-10-2022 | Kwartaaldividend 0.54 USD |
30-06-2022 | Kwartaaldividend 0.54 USD |
31-03-2022 | Kwartaaldividend 0.54 USD |
06-01-2022 | Kwartaaldividend 0.54 USD |
Geschiedenis van de jaarlijkse publicaties
Start boekjaar | december | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Omzet Miljoen USD | Gepubliceerd Verwachting Spread | 26 145 26 418 -1.03% | 42 518 42 189 0.78% | 46 385 46 366 0.04% | 46 159 45 911 0.54% | 45 006 44 731 0.62% | 45 793 |
EBITDA Miljoen USD | Gepubliceerd Verwachting Spread | 9 945 9 754 1.96% | 18 118 20 279 -10.65% | 20 493 21 878 -6.33% | 20 123 20 368 -1.2% | 17 498 18 255 -4.15% | 4 203 |
Bedrijfsresultaat (EBIT) Miljoen USD | Gepubliceerd Verwachting Spread | 8 199 8 540 -3.99% | 17 426 17 664 -1.35% | 19 830 19 963 -0.67% | 19 442 18 924 2.73% | 16 785 16 921 -0.8% | 3 989 |
Resultaat voor belastingen (EBT) Miljoen USD | Gepubliceerd Verwachting Spread | 4 975 0,00 - | -6 871 1 541 -545.88% | 8 098 7 644 5.94% | 7 713 7 912 -2.51% | 8 440 8 846 -4.59% | -18 524 |
Nettowinst (verlies) Miljoen USD | Gepubliceerd Verwachting Spread | 3 439 0,00 - | -9 015 1 269 -810.58% | 6 994 6 219 12.46% | 6 327 6 617 -4.39% | 8 025 7 823 2.58% | -3 954 |
WPA USD | Gepubliceerd Verwachting Spread | 0,00 0,00 - | -3,99 0,53 -851.84% | 3,12 2,78 12.07% | 2,95 2,97 -0.55% | 3,86 3,73 3.53% | -1,45 |
Datum van publicatie | 06/02/20 | 04/02/21 | 04/02/22 | 02/02/23 | 02/02/24 | - |
Geschiedenis van de driemaandelijkse publicaties
Start boekjaar | december | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Omzet Miljoen USD | Gepubliceerd Verwachting Spread | 11 985 11 998 -0.11% | 11 648 11 343 2.69% | 11 887 11 467 3.66% | 11 218 11 180 0.34% | 11 406 11 198 1.86% | 11 337 11 498 -1.4% | 11 226 11 811 -4.95% | 10 966 10 959 0.06% | 11 477 11 203 2.45% | 11 455 | 11 515 | 11 269 | 11 726 | 11 642 |
EBITDA Miljoen USD | Gepubliceerd Verwachting Spread | 4 832 5 087 -5.01% | 5 305 5 176 2.5% | 7 812 5 060 54.38% | 7 424 4 973 49.29% | 4 288 4 594 -6.66% | 5 030 4 732 6.3% | 4 268 6 031 -29.24% | 4 539 5 339 -14.98% | 3 816 4 833 -21.04% | -8 519 | 4 549 | 4 218 | 4 368 | |
Bedrijfsresultaat (EBIT) Miljoen USD | Gepubliceerd Verwachting Spread | 4 670 4 823 -3.17% | 5 267 4 848 8.63% | 5 229 4 563 14.58% | 4 836 4 622 4.62% | 4 110 4 248 -3.26% | 4 857 4 816 0.85% | 4 251 4 785 -11.16% | 4 360 4 206 3.66% | 3 630 3 663 -0.91% | -8 514 | 4 268 | 4 186 | 4 220 | 4 957 |
Resultaat voor belastingen (EBT) Miljoen USD | Gepubliceerd Verwachting Spread | 1 958 2 118 -7.55% | 2 209 2 139 3.27% | 1 859 1 767 5.21% | 2 770 2 808 -1.34% | 1 859 2 836 -34.44% | 2 137 2 216 -3.58% | 1 674 2 000 -16.28% | 2 302 | 2 226 | 2 268 | ||||
Nettowinst (verlies) Miljoen USD | Gepubliceerd Verwachting Spread | 2 372 1 419 67.16% | 1 278 | 1 421 1 423 -0.11% | 1 606 1 469 9.33% | 2 022 1 444 40.03% | 2 262 2 290 -1.24% | 2 073 2 165 -4.23% | 1 928 1 585 21.63% | 1 762 1 479 19.13% | -9 816 | 1 860 | 1 761 | 1 953 | |
WPA USD | Gepubliceerd Verwachting Spread | 1,07 0,96 11.85% | 0,59 0,86 -31.4% | 0,66 0,58 13.79% | 0,75 0,71 5.63% | 0,95 0,73 31.03% | 1,07 1,19 -10.08% | 0,99 1,16 -14.88% | 0,93 0,89 4.03% | 0,87 0,72 20.52% | -4,68 | 1,03 | 0,98 | 1,06 | 1,83 |
Datum van publicatie | 04/02/22 | 29/04/22 | 27/07/22 | 25/10/22 | 02/02/23 | 27/04/23 | 27/07/23 | 26/10/23 | 02/02/24 | - | - | - | - | - |